allantoic acid has been researched along with Hyperuricemia in 1 studies
allantoic acid: RN given refers to parent cpd; structure
allantoic acid : A member of the class of ureas that consists of acetic acid in which the two methyl hydrogens are replaced by carbamoylamino groups respectively.
Hyperuricemia: Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganson, NJ | 1 |
| Kelly, SJ | 1 |
| Scarlett, E | 1 |
| Sundy, JS | 1 |
| Hershfield, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout[NCT00111657] | Phase 2 | 30 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients who developed antibodies to PEG-uricase (NCT00111657)
Timeframe: baseline, then prior to infusions and 7 wks after last infusion
| Intervention | participants (Number) |
|---|---|
| Pegloticase | 15 |
The highest drug concentration in the blood after the first infusion of study drug. (NCT00111657)
Timeframe: 2 hours
| Intervention | mU/mL (Mean) |
|---|---|
| Single Arm - Pegloticase | 25.6 |
The lowest drug concentration in the blood after the first infusion of study drug. (NCT00111657)
Timeframe: 21 days after the infusion
| Intervention | mU/mL (Mean) |
|---|---|
| Single Arm - Pegloticase | 4.9 |
(NCT00111657)
Timeframe: Baseline to Day 105
| Intervention | Participants (Number) |
|---|---|
| Single Arm | 17 |
Count of tenderness and swelling of 68 joints (NCT00111657)
Timeframe: Basline and day 134
| Intervention | joints (Median) | |||
|---|---|---|---|---|
| Number of Tender joints at baseline | Number of Tender joints at day 134 | Number of Swollen jonts at baseline | Number of Swollen jonts at day 134 | |
| Pegloticase | 13 | 2 | 9 | 6 |
1 trial available for allantoic acid and Hyperuricemia
| Article | Year |
|---|---|
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Topics: Adult; Aged; Carbon Radioisotopes; Female; Gout; Humans; Hyperuricemia; Immunoglobulin G; Male; Midd | 2006 |